Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
With this, the company can start selling Ibuprofen in the European markets.
Better serving global partners and advancing healthcare innovation
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Syngene's collaboration with Zoetis started in 2011
Novavax’ clinical development program reported no severe allergic reactions
Philips demonstrates portfolio of smart connected imaging systems and integrated radiology workflow solutions designed to improve diagnostic confidence and clinical outcomes
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
Subscribe To Our Newsletter & Stay Updated
